Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas

References

• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Al-Hamadani M, Habermann TM, Cerhan JR, et al. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90(9):790–795.
   PubMed Web of Science ®Google Scholar
• Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443–459.
   PubMed Web of Science ®Google Scholar
• Sekhar J, Sanfilippo K, Zhang Q, et al. Waldenström macroglobulinemia: a surveillance, epidemiology, and end results database review from 1988 to 2005. Leuk Lymphoma. 2012;53(8):1625–1626.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: B-cell lymphomas version 6.2019; 2019; [cited 2019 Dec 4]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx
   Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Waldenström macroglobulinemia/lymphoplasmacytic lymphoma version 1.2020; 2019; [cited 2020 Jan 22]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx
   Google Scholar
• EMA Committee for Medicinal Products for Human Use. Revlimid (lenalidomide). Summary of opinion; 2019. Available from: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-revlimid-ii-107_en.pdf
   Google Scholar
• US FDA. FDA approves lenalidomide for follicular and marginal zone lymphoma; 2019. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lenalidomide-follicular-and-marginal-zone-lymphoma
   Google Scholar
• EMA Product Information. Zydelig (idelalisib). Summary of product characteristics; 2019. Available from: https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf
   Google Scholar
• ZydeligTM (idelalisib) Tablets for Oral Use. Full prescribing information. Foster City (CA): Gilead Sciences, Inc.; 2018.
   Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–1018.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2019;37(11):912–922.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010;116(1):106–114.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Fayad L, Delwail V, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012;119(16):3698–3704.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Morschhauser F, Bouabdallah K, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28(9):2169–2178.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Schuster SJ, Fowler NH, et al. Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study. J Clin Oncol. 2018;36(23):2405–2412.
   PubMed Web of Science ®Google Scholar
• Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129(16):2224–2232.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Chua N, Mayer J, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018;36(22):2259–2266.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, Flowers CR, et al. Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood. 2017;129(22):3037–3039.
   PubMed Web of Science ®Google Scholar
• Link BK, Day BM, Zhou X, et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol. 2019;184(4):660–663.
   PubMed Web of Science ®Google Scholar
• Gabrielli G, Broccoli A, Pellegrini C, et al. Idelalisib as a bridge to allogeneic transplantation in relapsed/refractory lymphoma with renal cancer: a case report. Clin Lymphoma Myeloma Leuk. 2020;20(1):e15–e17.
   PubMed Web of Science ®Google Scholar
• Marangon M, Pellegrini C, Argnani L, et al. Efficacy of idelalisib as bridge to allogeneic stem cell transplant in relapsed follicular lymphoma: a case report. Tumori. 2017;103(Suppl. 1):e41–e43.
   PubMedGoogle Scholar
• Denlinger NM, Epperla N, William BM. Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. Cancer Manag Res. 2018;10:615–624.
   PubMed Web of Science ®Google Scholar
• Oza A, Rajkumar SV. Waldenstrom macroglobulinemia: prognosis and management. Blood Cancer J. 2015;5:e394.
   PubMed Web of Science ®Google Scholar
• Jacobsen E, Ďuraš J, Ardeshna K, et al. Characterization of duvelisib in patients with refractory marginal zone lymphoma: data from the phase 2 DYNAMO trial. Clin Lymphoma Myeloma Leuk. 2019;19:S312–S313.
   Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med. 2015;372(15):1430–1440.
   PubMed Web of Science ®Google Scholar
• Bird ST, Tian F, Flowers N, et al. Idelalisib for treatment of relapsed follicular lymphoma and chronic lymphocytic leukemia: a comparison of treatment outcomes in clinical trial participants vs medicare beneficiaries. JAMA Oncol. 2020;6(2):248–254.
   PubMed Web of Science ®Google Scholar
• Eyre TA, Osborne WL, Gallop-Evans E, et al. Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma. Br J Haematol. 2018;181(4):555–559.
   PubMed Web of Science ®Google Scholar
• Sharman JP, Coutre SE, Furman RR, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019;37(16):1391–1402.
   PubMed Web of Science ®Google Scholar
• Cuneo A, Barosi G, Danesi R, et al. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: a multidisciplinary position paper. Hematol Oncol. 2019;37(1):3–14.
   PubMed Web of Science ®Google Scholar